Owning the revenue engine in a hospital group

The phrase arrives in a job description or a board conversation: the marketing head should “own the revenue engine”. Everyone nods. Nobody defines it. A year later the same person is being asked why revenue at a unit is flat when enquiries are up, and discovers that the engine they were meant to own has six parts they never had a key to.

I know this because it happened to me. A unit P&L review, a quarter in which digital enquiries had grown steadily, and a revenue line that had not moved. The unit head looked at me. The CFO looked at me. I had a slide about enquiries and nothing to say about why they had not become money. The answer, when we found it, was in the operating theatre schedule and the payer mix — two places marketing had never been invited to look.

Owning the revenue engine means being accountable for the whole line, not the slice you can advertise. It is a different job from marketing, even when the same person does it. This is what the whole line contains, which pieces marketing genuinely controls, and what changes when you take on the rest.

The engine has eight parts

Hospital revenue is not a funnel. It is closer to a chain of multipliers, and a weak link anywhere caps the result regardless of how strong the rest is. Roughly, the parts are these:

• Demand. People who want to come: OPD footfall, enquiries, emergency arrivals, referred patients, institutional cases.
• Conversion. How much of that demand becomes an appointment, and how much of an appointment becomes an admission or a procedure.
• Capacity. Beds, ICU beds, theatre slots, cath lab hours, consultant time, diagnostic throughput. Revenue cannot exceed what capacity can process.
• Mix. Which specialties and which procedures fill that capacity. A bed-day in a high-contribution specialty and a bed-day in a low one are not the same bed-day.
• Pricing. Package rates, room-category tariffs, the rack rate, and the discipline of the estimate.
• Payer. Who pays: cash, insurance through a TPA, corporate, government scheme. Each realises differently and collects on a different clock.
• Retention. Whether the patient and the family come back for the next episode, the follow-up, the annual check, the second child.
• Referral. Whether that patient and their treating doctor send others.

Marketing, in most hospital groups, has budget authority over the first and partial authority over the second. The revenue line depends on all eight. That is the gap the phrase “own the revenue engine” is quietly pointing at.

What marketing controls, influences and merely watches

Be honest about this with yourself before anyone else does it for you.

You control demand from the local catchment, and you control conversion up to the point of the first appointment: the enquiry channels, the contact centre scripts, the booking experience, the follow-up cadence. Those are yours, budget and outcome.

You influence mix, because what you promote shapes what walks in. You influence retention, because the CRM and the post-discharge programme are usually in your function. You influence referral demand at the margin — the doctor-facing communication, the referrer portal, the outreach calendar — but the relationship that actually moves a referral belongs to the consultant and the medical director.

You watch capacity, pricing and payer. You do not set the theatre schedule. You do not negotiate the TPA tariff. You do not decide whether the unit takes a government scheme. And yet these three determine more of the revenue line in a mature unit than everything you control put together.

The marketing head who does not know this is dangerous, because they will keep buying demand into a unit that cannot process it. The one who knows it and stays inside their lane is safe but limited. The growth seat exists for the person who knows it and takes responsibility anyway.

Why more demand can make the number worse

This is the failure mode that finally taught me the difference between the two jobs.

A unit near capacity in its strong specialties receives a demand push. The campaign works. Enquiries rise, appointments rise, and the theatre list is already full three weeks out. The new patients wait, some of them go elsewhere, and the money spent acquiring them is gone. Or the patients who do get through are in the specialties with slack — which have slack for a reason, usually because contribution is thin. Occupancy ticks up. Yield per occupied bed goes down. The CFO sees a busier hospital earning less per bed and, reasonably, asks what marketing thinks it is doing.

Payer drift does the same thing more slowly. A campaign that pulls in scheme-eligible patients fills beds at a tariff the unit may lose money on, and displaces cash and insured patients who would have paid more. The volume chart looks excellent for two quarters. Then receivables lengthen, realisation drops, and the unit’s margin is worse than before the campaign.

None of this is an argument against demand. It is an argument that demand without the other seven parts is not growth. It is activity.

Capacity is the part marketing pretends not to see

Every unit head knows where the capacity constraint is. Very few marketing heads do, because nobody has ever asked them to care.

Sit with the unit head and the medical director and ask three questions. Which specialties are turning patients away or making them wait beyond what the market tolerates? Which theatre or lab slots are empty on which days? Which consultants have OPD slots going unbooked? The answers tell you where demand is worth buying and where it is worthless. They also tell you where the honest growth case is not a campaign at all — it is a second cath lab, a weekend theatre list, or a consultant hire — and the growth leader’s job is to build that case and carry it into the executive committee alongside the CFO’s capital queue.

That is the first real test of whether you own the engine: can you argue for capacity, with a payback model, in the same meeting where you used to argue for media spend? The first time I did it, the case was rougher than anything I would have accepted from an agency. It was still the most useful thing I had brought to that room in a year, because it was the first time growth had shown up with a proposal that cost money in the capital queue rather than the marketing line.

Mix and pricing need partners you do not manage

Mix is set by clinicians, capacity and the market. Pricing is set by finance, the payer contracts and the front desk. You cannot own either alone, and the mistake is to try.

What you can do is make mix visible and make it a decision. Most groups have a contribution view by specialty somewhere in finance. Get it into the growth review. When you see that a specialty consuming a large share of marketing budget generates thin contribution, you have a conversation to start — not to cut the specialty, which may be strategically essential, but to stop paying to grow it faster than its economics deserve.

On pricing, your leverage is narrower than people assume. Inside the revenue engine, the piece that belongs to you is the discipline between the estimate and the bill, and the governance of front-desk discounting. Both are growth problems dressed as operations problems, because both determine whether the patient you acquired at real cost pays what you modelled.

Payer is where revenue and cash part company

The revenue line and the cash line are different lines, and growth leaders who read only the first eventually get ambushed by the second.

A TPA-empanelled patient is revenue on discharge and cash weeks or months later, less whatever the claim review disallows. A scheme patient is revenue at a fixed tariff and cash whenever the scheme pays, which is not a date anyone can promise. A corporate account may be excellent volume and a slow debtor. The CFO carries all of this as working capital, and every campaign that shifts the payer mix shifts the working capital with it.

Owning the engine means owning that conversation. Which payers do we want more of, at which units, in which specialties? Which empanelments should we pursue, and which should we let lapse? Those are commercial decisions with a growth logic and a finance logic, and they need one person who can hold both.

Retention and referral are the parts that compound

Acquisition is linear: spend, get patients, spend again. Retention and referral compound, and they are the parts of the engine most groups leave unowned.

A family that had a good experience with a paediatric admission will return for the next three years of illness and, more valuably, will tell other families. A treating doctor who was kept informed through a referred patient’s stay will refer again. A corporate HR head who found the billing clean will renew. None of these behaviours needs a media budget. All of them need someone responsible for the operational moments that produce them: the discharge summary reaching the referring doctor, the follow-up call that actually happens, the corporate invoice that does not need three corrections.

In my experience the referral engine in particular sits in a gap between marketing, medical administration and the unit head, and each assumes another is running it. The growth leader’s move is to name an owner, a metric — active referrers and their share of cases — and a monthly review. Nothing more sophisticated is required at first. Ownership is the missing piece, not technology.

What accountability for the whole line requires

Taking on the whole line is not a title change. It is a change in what you are allowed to see, what you are allowed to say, and what happens to you when the number moves.

You need a seat in the unit P&L review, not a slot on its agenda. The difference is whether you are presenting to the review or part of it, and whether you hear the capacity, payer and pricing discussion or only the marketing one.

You need a shared scorecard with the unit heads. If you are measured on enquiries and they are measured on EBITDA, you will be in conflict by the second quarter, and they will win, because their number is the real one. The scorecard has to be revenue, contribution, occupancy and yield, with growth and the unit signing the same page.

You need the right to decline volume. A growth leader who cannot say “we will not pursue that scheme at that unit” or “we are pausing acquisition in that specialty until the theatre list clears” is a marketing head with a longer title.

And you need a named owner for each of the eight parts, even where that owner is not you. The engine does not need one person to run everything. It needs one person who knows who runs each part, what the number is, and what happens when it slips.

If you’re starting this next quarter

1. Get the last twelve months of the management pack for every unit and read the revenue, occupancy, yield, payer mix and receivables lines before you read anything about marketing.
2. Sit with each unit head and medical director and map the capacity constraint by specialty. Write it down. This is your demand map from now on.
3. Ask finance for contribution by specialty and payer. Where it does not exist, help build an approximate version. Do not wait for a perfect one.
4. Rewrite the growth scorecard around revenue, contribution, occupancy and yield. Keep enquiries and conversion as inputs, not headlines.
5. Name an owner for referral and for retention at each unit. Give each one number and a monthly slot.
6. Choose one capacity case — a theatre list, a consultant, a lab slot — and take it to the executive committee with a payback model. Whether it is approved matters less than whether you are now the person who brings such cases.
7. Ask for the seat in the P&L review. If the answer is no, ask what would need to be true for it to be yes, and go and make that true.

The engine was always eight parts. Marketing was just the one with a budget line and a slide.

Questions people ask